Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.

Turk, HACI; Aliyev, A; Celik, RS; Seker, MESUT; Coban, E; Demir, T; Baydas, T; Kocyigit, ABDÜRRAHİM

doi:10.1016/j.currproblcancer.2019.06.009

Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.

Turk H. M., Aliyev A., Celik R., Seker M., Coban E., Demir T., ...Daha Fazla

Current problems in cancer, cilt.44, sa.1, ss.100497, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 44 Sayı: 1
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.currproblcancer.2019.06.009
Dergi Adı: Current problems in cancer
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
Sayfa Sayıları: ss.100497
Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

Objective: M30 and M65 levels reflect tumor cell activity in patients with epithelial cancer. Cytokeratin 18 is one of the cell skeletal elements. M30 is a apoptotic marker of cytokeratin 18. M65 levels are both an apoptosis and a necrosis marker. The aim of our study was to determine the predictive value of M30 and M65 levels in neoadjuvant treatment of breast cancer.